- The Asian session brought strong gains across major equity benchmarks; the Nikkei rose more than 1.2%, while Hong Kong’s Hang Seng gained 1.6%. The market focus was on Samsung and SK Hynix deal with OpenAI; SK Hynix shares reached an 25-year high (up 9%), while Samsung gained more than 4%. On the macro side, consumer sentiment in Japan showed a slight improvement, edging up to 35.3 from 35.2 and 34.9 previously.
- The rally in Asia translated into improved sentiment for both European and U.S. index futures, with the US100 climbing 0.25% toward the 25,100 level. At 9 AM GMT, eurozone labor market data will be released, followed by U.S. jobless claims at 12:30 PM GMT and a revision of durable goods orders at 2 PM GMT
- Yesterday’s weaker-than-expected ADP employment data was welcomed by markets, fueling expectations of additional Fed rate cuts later this year. Tomorrow NFP report will be probably delayed, leaving the Fed with quite dovish labour market data, suggesting even 2 more cuts this year.
- According to Goldman Sachs, the likelihood of accelerated economic growth in the U.S. has now increased. On the other hand, S&P Global warned that the ongoing U.S. government shutdown is adding uncertainty to the broader economic outlook.
- Fitch Ratings commented to the US government hutdown: 'A protracted disruption could slightly slow US economic growth. (...) The macroeconomic impact of the shutdown is limited in the near term.' Markets see the shutdown as a potentially dovish, which support gold but impact the US Dollar
- Intel shares gained yesterday after the Semafor informed that the company is now in early talks to add AMD as a foundry customer. Also, Pfizer shares surged more than 6% after upgraded rating by BMO analysts and Politico's report that Trump delayed pharma tariffs to negotiate drug prices.
- Trump last week threatened triple-digit tariffs on pharmaceutical imports beginning Wednesday. The White House now says it may not have to impose them. According to a White House official, the Trump administration has paused its plan to impose the duties in order to negotiate agreements with pharmaceutical giants to avoid higher tariffs on their name-brand products, such as the one announced with Pfizer.
🔴 ISM Index Shows Troubling Signs, But Market Thrives on De-escalation Hopes
Market Wrap – Data Confirms BoJ Intervention. Waiting for US ISM (05.01.2026)
Chart of the Day: Intervention on the Yen? Tokyo Challenges Speculators (01.05.2026)
🔵 ECB Conference (LIVE)
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.
